Reaching Underserved Communities

New HIV infections are on the decline, but we’re still a long way from ending the epidemic — especially in the US South, the new epicenter of the HIV crisis, and among African American and Latino men who have sex with men (MSMs), African American women, and transgender people. In 2012, Gilead released Truvada for PrEP, a pill that can prevent HIV, but not enough people — especially in those key, disproportionately affected communities — know about it, or about their risk status and sexual health options generally.

Gilead’s goal was to ensure that anyone who might benefit from PrEP had the information they needed to initiate a conversation about HIV prevention with their healthcare provider. Precision conducted a comprehensive audit of HIV stakeholders, including leading advocates and healthcare professionals. We then created a roadmap for outreach to impacted communities, which included recommending a TV advertising campaign for Truvada — the first in its history — and dramatically expanding Gilead’s influencer outreach, as well as expanding support options like online chat features for people seeking information about PrEP.